To investigate the possibility of improving the efficacy of current treatment regimens for paclitaxel-resistant lung cancer, a paclitaxel-resistant lung cancer cell line was co-treated with the PLK1 inhibitor volasertib combined with the USP7 inhibitor P22077 (Figure 5). Here, PLK1 is linked to lung cancer.